Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 781 - 800 results of 104,490 for search '(( 5 ((a decrease) OR (mean decrease)) ) OR ( e ((fold decrease) OR (point decrease)) ))', query time: 0.90s Refine Results
  1. 781
    TH588 effectively decreases cellular survival in heterogeneous neuroendocrine tumor cells.

    TH588 effectively decreases cellular survival in heterogeneous neuroendocrine tumor cells. by Elke Tatjana Aristizabal Prada (833927)

    Published 2017
    Save to List
    Saved in:
  2. 782
    Effects of A1AR expression on response to hypoxia at E9.5 and E12.5.

    Effects of A1AR expression on response to hypoxia at E9.5 and E12.5. by Daniela L. Buscariollo (140729)

    Published 2013
    “…In hypoxia, E9.5 A1AR +/− heart rates decreased then returned to baseline levels following recovery in room air (p<0.0001 and p<0.01, for t = 25 and t = 40 compared to t = 0, respectively). …”
    Save to List
    Saved in:
  3. 783
    The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages.

    The sialidase inhibitor Neu5Ac2en decreases growth of wt <i>C. canimorsus 5</i> in presence of macrophages. by Manuela Mally (348810)

    Published 2013
    Save to List
    Saved in:
  4. 784
    Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism.

    Compatible pollen triggers a decrease in S-RNase transcript levels by a post-transcriptional mechanism. by Bolin Liu (59887)

    Published 2009
    Save to List
    Saved in:
  5. 785
    A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner.

    A hypoglycaemic <i>milieu</i> decreases NCS viability in a dose-dependent manner. by Shiva Mansouri (2838086)

    Published 2016
    Save to List
    Saved in:
  6. 786
    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells.

    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

    Published 2014
    Save to List
    Saved in:
  7. 787
    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells.

    FASN inhibitors result in decreased ΔΨm and increased superoxide production in melan-a cells. by Franco A. Rossato (588513)

    Published 2014
    Save to List
    Saved in:
  8. 788
    Resveratrol decreases CYP17A1 and CYP21A2 protein expression.

    Resveratrol decreases CYP17A1 and CYP21A2 protein expression. by Nesa Marti (3851059)

    Published 2017
    “…<p>A. Gene expression profiling by qRT-PCR was performed for CYP17, CYP21 and their cofactor POR in H295R cells grown under normal conditions (GM), starvation conditions (SM), metformin (Met) (1mM) treatment and under resveratrol (RSV) (5<u>μM)</u> treatment. …”
    Save to List
    Saved in:
  9. 789
    Knockdown of factors in the 5′SS recognition complex U1 globally decreases intronic miRNA levels.

    Knockdown of factors in the 5′SS recognition complex U1 globally decreases intronic miRNA levels. by Maja M. Janas (200408)

    Published 2011
    Save to List
    Saved in:
  10. 790
    <i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort

    <i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

    Published 2014
    Save to List
    Saved in:
  11. 791
    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells.

    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

    Published 2013
    Save to List
    Saved in:
  12. 792
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 793
    CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i><sup><i>ECKO</i></sup> mice and lesions in the retina of <i>Ccm2</i><sup><i>ECKO</i></sup> mice.

    CD5-2 decreases established CCM lesions in the hindbrain of <i>Ccm2</i><sup><i>ECKO</i></sup> mice and lesions in the retina of <i>Ccm2</i><sup><i>ECKO</i></sup> mice. by Jia Li (160557)

    Published 2020
    Save to List
    Saved in:
  14. 794
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 795
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 796
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 797
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 798
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 799
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 800
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: